Dentsply Sirona Reports Third Quarter 2026 Results

News Summary Q3 2026 net sales of $836 million Q3 2026 GAAP gross margin of 52.9% , GAAP diluted loss per share of ($0.01) Q3 2026 adjusted gross margin of 54.5% , adjusted EBITDA margin of 17.3% , adjusted EPS of $0.29 Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™ portfolio with the launch of the Surity ™ Urinary Management System Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona"...